Long-term efficacy beyond one year, including weight maintenance after treatment cessation and durability of metabolic improvements, remains incompletely characterized
In Phase 3 trials, nausea affected up to 42.4% of people, diarrhoea up to 34.1%, constipation up to 26.1%, and vomiting up to 25.3%, depending on the dose
Ongoing clinician access should be available throughout your treatment for dose adjustments, side effect management, and progress monitoring
If dissolution takes significantly longer or appears incomplete, this may indicate compromised product quality or improper storage before reconstitution
The FDA has issued repeated warnings about these peptides: contamination, dosage variability, companies making false claims
Jones, Dr